Renal Denervation Devices Market Expected to Reach USD 387 Million by 2032 with a Remarkable 37.2% CAGR, According to Straits Research

Core Insights - The global renal denervation devices market was valued at USD 54.26 million in 2023 and is projected to reach USD 387 million by 2032, growing at a CAGR of 37.2% from 2024 to 2032 [1][11]. Market Drivers - The increasing prevalence of hypertension, particularly among the aging population, is expected to drive demand for renal denervation devices [2][16]. - Lifestyle factors such as smoking and poor dietary habits are contributing to the rise in hypertension cases, further boosting market demand [4][9]. - Innovative research and development in hypertension treatment are creating new commercial opportunities, with successful studies on devices like the Peregrine System Infusion Catheter demonstrating safety and efficacy [8][16]. Regional Insights - Europe holds the largest market share for renal denervation devices, with an estimated CAGR of 37.5% during the forecast period, driven by a growing geriatric population and increasing cases of therapy-resistant hypertension [9][10]. - The Asia-Pacific region is expected to account for USD 90 million by 2030, with a CAGR of 37.6%, fueled by rising hypertension prevalence and awareness of treatment benefits [20]. Market Segmentation - The renal denervation devices market is segmented by technology into Radiofrequency-based, Ultrasound-based, and Micro-infusion-based, with Radiofrequency-based devices holding the largest market share and a projected CAGR of 37.1% [11][23]. - The market is also segmented by end users, including hospitals, clinics, and ambulatory surgery centers [23]. Competitive Landscape - Key players in the renal denervation devices market include Medtronic PLC, St. Jude Medical Inc., ReCor Medical Inc., and Ablative Solutions Inc., among others [22]. - Companies are focusing on R&D, mergers and acquisitions, and product launches to enhance their market position [10].